12:00 AM
Jun 26, 2001
 |  BC Extra  |  Financial News

Xoma raises $45 million

XOMA, which is in Phase III testing of its Xanelim anti-CD11a monoclonal antibody for psoriasis, raised $45 million through the sale of 3 million shares...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >